Methods for inducing an immune response against human immunodeficiency virus infection in subjects undergoing antiretroviral treatment

A method of inducing an immune response against a human immunodeficiency virus (HIV) in an HIV-infected human subject undergoing antiretroviral therapy (ART), the method comprising:

• (i) administering to the human subject a primer vaccine comprising an immunogenically effective amount of one or more adenovirus 26 (Ad26) vectors encoding one or more mosaic HIV antigens comprising the amino acid sequences selected from the group consisting of SEQ ID NOs:
• 1, 3, and 4 and a pharmaceutically acceptable carrier;
• and
• (ii) administering to the human subject a booster composition comprising an immunogenically effective amount of one or more MVA vectors encoding one or more mosaic HIV antigens comprising the amino acid sequences selected from the group consisting of SEQ ID NOs:
• 1-4 and a pharmaceutically acceptable carrier,
• wherein the primer vaccine is re-administered at about 10-14 weeks after the primer vaccine is initially administered;
• the booster vaccine is first administered at about 22-26 weeks after the primer vaccine is initially administered;
• and the booster vaccine is re-administered at about 46-50 weeks after primer vaccine is initially administered;
• and
• wherein the human subject initiated ART during acute HIV infection.